Track topics on Twitter Track topics that are important to you
Vizient, Inc. Vizient, Inc. PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Vizient, Inc. Vizient, Inc. articles that have been published worldwide.
We have published hundreds of Vizient, Inc. Vizient, Inc. news stories on BioPortfolio along with dozens of Vizient, Inc. Vizient, Inc. Clinical Trials and PubMed Articles about Vizient, Inc. Vizient, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Vizient, Inc. Vizient, Inc. Companies in our database. You can also find out about relevant Vizient, Inc. Vizient, Inc. Drugs and Medications on this site too.
Alvimopan (Entereg), a peripherally acting opioid receptor antagonist, is effective in reducing the rate of postoperative ileus and length of hospital stay in patients undergoing colorectal surgery, and is now approved for use after radical cystectomy (RC). Using data from Vizient (formerly University Health System Consortium), we assessed the utilization of alvimopan and its effect on perioperative factors after RC.